Case report: Daratumumab for treatment of refractory late or chronic active antibody-mediated rejection in renal allograft recipients with high levels of de novo donor-specific antibodies

Case report: Daratumumab for treatment of refractory late or chronic active antibody-mediated rejection in renal allograft recipients with high levels of de novo donor-specific antibodies

BackgroundLate or chronic active antibody-mediated rejection (AMR) associated with de novo donor-specific antibodies (dnDSA) after renal transplantation is a great clinical challenge because it is often resistant to conventional therapies. Daratumumab, an anti-CD38 monoclonal antibody that can deple...

Full description

Bibliographic Details
Main Authors: Lan Zhu, Zhiliang Guo, Daqiang Zhao, Rula Sa, Guangyuan Zhao, Hui Guo, Gang Chen
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-01-01
Series:Frontiers in Immunology
Subjects:
kidney transplantation
daratumumab
chronic active antibody-mediated rejection
donor specific antibodies
HLA-DQ
case report
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.1087597/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.1087597/full

Similar Items